Kaos Capital Takes 4.9% Stake in BioRestorative Therapies (BRTX); Stock Surges Pre-Market

Kaos Capital disclosed a 4.9% passive stake in BioRestorative Therapies Inc. (BRTX) in a Schedule 13G filing on May 27, 2026, sending the biotech’s shares sharply higher in pre-market trading. The regulatory filing signals a notable vote of confidence from the investment firm. BRTX stock surged in electronic trading before the opening bell. BioRestorative Therapies focuses on developing adult stem cell-based therapies for degenerative disc disease and metabolic conditions.